Read Our Blog

Call Us: (913) 544-1199

The Modified-Release Panacea: Multiparticulates

Amanda Stevenson-Grund - Friday, December 01, 2017

Among all the systems used for controlled release, multiparticulate systems are the most commonly used and can offer many unique advantages.” – Wen and Park, editors. Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice. John Wiley & Sons, 2011.

 Round spheres represent multiparticulates in drug delivery

Modified-release dosage forms have many formats: extended release, delayed release, sustained release, targeted release and pulsatile release. Each of these release profiles has potential drug formats to support creating the correct pharmacokinetic curve. Multiparticulates, in particular, are well-suited for modified-release applications. As stated by Jagdale, et al.,Multiparticulate systems offer various advantages over single unit systems.  These advantages include no risk of dose dumping, flexibility of blending units with different release patterns, as well as short and reproducible gastric residence times.”

 More >

The Significance of Solubility in Oral Drugs

Amanda Stevenson-Grund - Friday, November 10, 2017

It is generally recognized that poor solubility is one of the most frequently encountered difficulties in the field of pharmaceutics.” – Kumar and Singh. American Journal of Pharmacological Sciences. 2013; 4: 67.

Two oral drugs in liquid indicate poor solubility

Many challenges slow the pace of drug development. One such challenge is drug solubility. Poor solubility causes low bioavailability and a decreased chance of drug administration resulting positive clinical outcomes.

 More >

Orbis Biosciences awarded CPhI Excellence in Formulation Award

Amanda Stevenson-Grund - Monday, October 30, 2017

Orbis Biosciences receives a CPhI Pharma Excellence in Pharma Award

CPhI Worldwide, the world’s leading pharmaceutical and manufacturing conference, hosted more than 42,000 visitors October 24 -26 in Frankfurt, Germany. The event, which included more than 2,500 exhibitors from 153 countries, represents every sector of the pharmaceutical market. The culmination of this conference is the CPhI Excellence in Pharma Awards Gala where key industry innovations are recognized from across the globe for their innovative technologies.

 More >

Intraympanic Injections Provide Local Delivery of Disease Fighting Drugs to the Inner Ear

Amanda Stevenson-Grund - Friday, October 13, 2017

Medicines, called antivirals, may decrease the risk of health problems and hearing loss in some infected babies who show signs of congenital CMV infection at birth.” – CDC, Cytomegalovirus (CMV) and Congenital CMV Infection. Accessed June 24, 2017

An ear represents antiviral, intratympanic drug delivery for cytomegalovirus

Cytomegalovirus can cause devastating long-term effects, such as hearing loss, for infants diagnosed with the disease. Physicians often use antiviral medication to treat cytomegalovirus by relying on systemic exposure of the drug to treat the infection. Emerging localized delivery approaches, such as intratympanic injection, offer the potential to provide incremental protection against the infection by delivering drugs directly to the inner ear.

 More >

Diverse Responses to Cytomegalovirus Drive the Need for Population-Specific Treatment Approaches

Amanda Stevenson-Grund - Friday, September 29, 2017

Born This Way: Congenital Cytomegalovirus

Amanda Stevenson-Grund - Friday, September 15, 2017

About one out of every 200 babies are born with congenital CMV infection.”
 –
CDC, Cytomegalovirus (CMV) and Congenital CMV Infection. Accessed May 6, 2017

Pediatric patients with congenital cytomegalovirus can experience physical disabilities

Most parents of newborn babies experience joy when welcoming a new member of the family. However, parents of children with congenital cytomegalovirus instead experience the fear that their children may be affected by the physical and intellectual disabilities that can accompany this disease. In very extreme cases, congenital cytomegalovirus can lead to death in newborns and young children.

 More >

Strengthening Solubility: Advantages of Increased Drug Solubility

Amanda Stevenson-Grund - Friday, September 01, 2017

Poorly water-soluble drug candidates are becoming more prevalent. It has been estimated that approximately 60–70% of the drug molecules are insufficiently soluble in aqueous media,”Gupta et al., Formulation Strategies to Improve the Bioavailability of Poorly Absorbed Drugs with Special Emphasis on Self-Emulsifying Systems. ISRN Pharmaceutics: 2013; 2013

 

Poorly water soluble drugs continue to pose significant formulation challenges. Solubility challenges have driven CDMOs to employ a portfolio of technologies to address solubility challenges. 

 More >

Obviously Orodispersible: When ODTs are a Good Fit

Amanda Stevenson-Grund - Friday, August 11, 2017

Orodispersible tablets (ODT) can be administered to any patients having difficulty in swallowing.” – Hannan, et al. Indian J Pharm Sci. 2016; 78: 2-7

A pediatric patient with dysphagia and low medication adherence takes an orodispersible tablet (ODT).

Demand for patient-friendly formulations is increasing to address the diverse needs of multiple patient populations. As demand increases, pharmaceutical companies continue to look for innovative solutions to meet a broad range of patient needs. Orodispersible tablets (ODTs) can be a good fit for pediatric patients, geriatric patients and patients with dysphagia, as well as patients with low medication adherence.

 More >

The Power of Powder: Dispersible Powder and Its Many Formats

Amanda Stevenson-Grund - Friday, July 28, 2017

Powders and granules may be given to children from birth provided they can be administered as a liquid preparation.” – European Medicines Agency, Guideline on pharmaceutical development of medicines for paediatric use. 2013: 7

Medication in powder format

Powder medications predominate in many countries, such as Finland and Italy, and are starting to grow in popularity in the United States, according to Brion et al. in Acta Paediatrica. The power of powder lies in its many formats and kid-friendly features.

 More >

Extended Release in Parenteral Drugs: Designed with Patients in Mind

Amanda Stevenson-Grund - Friday, July 14, 2017

Several solutions to the problem of discontinuous access to pharmacotherapy are being developed in the form of new, long-acting drug-delivery systems, which gradually release medication over a period of several days or weeks with a single application.” – Siegel, Psychiatry (Edgmont). 2005; 2: 22-31

 A patient holds an extended-release parenteral drug

Like a tailored suit, some things just fit well. This is true in pharmaceuticals. Drugs with certain characteristics are often a good fit for specific conditions and diseases. For example, extended-release parenteral drugs have many benefits, which make them good candidates for psychiatric conditions and chronic pain.

 More >